柴胡皂苷D对大鼠免疫性肝纤维化的保护作用及其机制研究

黄祎; 夏莉; 雷青松; 张长江; 刘华宝; 李麟

doi:10.16016/j.2097-0927.202111062

您当前的位置：

首页 >

文章列表页 >

柴胡皂苷D对大鼠免疫性肝纤维化的保护作用及其机制研究

基础医学 | 更新时间：2026-01-09

- 柴胡皂苷D对大鼠免疫性肝纤维化的保护作用及其机制研究
- Protective effects and mechanism of saikosaponin D on immune hepatic fibrosis in rats
- 陆军军医大学学报 2022年44卷第14期页码：1410-1420
- 作者机构：
  
  1.400021 重庆，重庆市中医院肝病科
  2.400030 重庆，重庆大学附属肿瘤医院肿瘤放射治疗中心
- 作者简介：
  
  [李麟，E-mail：lilin515626@126.comLI Lin, E-mail: lilin515626@126.com
- 基金信息：
  
  重庆市自然科学基金面上项目(cstc2019jcyj-msxmX0049);重庆市科研院所绩效激励引导专项(jxyn2020-4)
- DOI：10.16016/j.2097-0927.202111062
  中图分类号： R282.71;R285.5;R575
- 收稿：2021-11-09，
  
  修回：2022-03-01，
  
  纸质出版：2022-07-30
- 稿件说明：
移动端阅览
黄祎, 夏莉, 雷青松, 等. 柴胡皂苷D对大鼠免疫性肝纤维化的保护作用及其机制研究[J]. 陆军军医大学学报, 2022,44(14):1410-1420.

Yi HUANG, Li XIA, Qingsong LEI, et al. Protective effects and mechanism of saikosaponin D on immune hepatic fibrosis in rats[J]. Journal of Army Medical University, 2022, 44(14): 1410-1420.
黄祎, 夏莉, 雷青松, 等. 柴胡皂苷D对大鼠免疫性肝纤维化的保护作用及其机制研究[J]. 陆军军医大学学报, 2022,44(14):1410-1420. DOI： 10.16016/j.2097-0927.202111062.

Yi HUANG, Li XIA, Qingsong LEI, et al. Protective effects and mechanism of saikosaponin D on immune hepatic fibrosis in rats[J]. Journal of Army Medical University, 2022, 44(14): 1410-1420. DOI： 10.16016/j.2097-0927.202111062.

摘要

目的

结合网络药理学分析与动物实验验证，探讨柴胡皂苷D(

saikosaponin D

，SSD)对猪血清诱导的大鼠免疫性肝纤维化的保护作用及机制。

方法

网络药理学分析方法获得SSD与自身免疫性肝病的潜在靶点，利用STRING数据库和Cytoscape软件构建蛋白相互作用网络图。利用DAVID数据库对潜在靶点进行KEGG通路富集分析。制备大鼠免疫性肝纤维化模型，SSD干预后ELISA检测大鼠血清ALT、AST、TNF-α、IL-1β和IL-18水平，HE染色观察大鼠肝脏病理改变，Western blot检测大鼠肝脏组织中NLRP3、ASC、Caspase-1、GSDMD、TLR4、Myd88、p65及p-p65蛋白的表达。

结果

通过筛选获得SSD与自身免疫性肝病的潜在靶点177个，KEGG富集分析得到与免疫系统相关的通路主要包括NOD样受体信号通路等，获得潜在靶点在NOD样受体信号通路中的富集情况。实验研究显示与模型组

比较，高剂量SSD可显著降低大鼠血清中ALT和AST水平(

0.05)；病理组织学检测显示SSD可显著改善大鼠肝脏纤维化程度，减轻肝脏损伤；ELISA检测显示中、高剂量SSD可显著降低大鼠血清中TNF-α、IL-1β和IL-18的水平(

0.05)；Western blot检测显示SSD可明显下调NLRP3、ASC、Caspase-1、GSDMD、TLR4、Myd88和p65蛋白的水平，并抑制p65的磷酸化。

结论

SSD能减少免疫性肝纤维化大鼠血清中炎性因子释放、减轻肝脏细胞损伤，其机制可能与调控TLR4/NF-κB和NLRP3炎症小体信号通路有关。

Abstract

Objective

To explore the effects and mechanism of saikosaponin D (SSD) on immune hepatic fibrosis induced by porcine serum in rats through network pharmacology analysis and animal experimental verification.

Methods

The potential targets for SSD and autoimmune hepatic diseases were obtained based on network pharmacology analysis

and the protein interaction network was constructed using STRING database and Cytoscape software. Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis was subsequently performed with DAVID database. Then the rat model of immune hepatic fibrosis was prepared and further intervened with SSD. Serum levels of ALT

AST

TNF-α

IL-1β and IL-18 were measured by ELISA. The pathological changes of rat liver were observed using HE staining; and Western blotting was conducted to detect the ptotein expression of NLRP3

ASC

Caspase-1

GSDMD

Toll-like receptor 4 (TLR4)

myeloid differentiation primary response 88 (Myd88)

p65 and p-p65 in rat liver tissues.

Results

A total of 177 potential targets of SSD and autoimmune hepatic diseases were collected. Enrichment analysis showed that the immune system-related pathways were mainly NOD-like receptor signaling pathway

and the enrichment of potential targets in this signaling pathway was obtained. As compared with the model group

high-dose SSD significantly reduced the serum levels of ALT and AST in rats (

0.05)

and remarkably improved hepatic fibrosis and alleviated liver injury in rat

s. ELISA indicated notable declines in TNF-α

IL-1β and IL-18 levels in rats after intervention of medium- and high-dose SSD (

0.05). Western blotting also suggested that SSD greatly down-regulated the protein levels of NLRP3

ASC

Caspase-1

GSDMD

TLR4

Myd88 and p65

and inhibited the phosphorylation of p65.

Conclusion

SSD reduces the release of inflammatory factors in serum and alleviates the injury of liver cells in rats with immune hepatic fibrosis

which may be related to the regulation of TLR4/NF-κB and NLRP3 inflammasome signaling pathways.

关键词

Keywords

references

WEISKIRCHEN R, TACKE F. Liver fibrosis: from pathogene-sis to novel therapies[J]. Dig Dis, 2016, 34(4): 410-422. DOI: 10.1159/000444556.

徐列明, 刘平, 沈锡中, 等. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 中国中西医结合杂志, 2019, 39(11): 1286-1295. DOI: 10.7661/j.cjim.20190916.314.

XU L M, LIU P, SHEN X Z, et al . Chinese guidelines for the diagnosis and treatment of liver fibrosis with integrated Chinese and Western medicine (2 019)[J ] . Chin J Integr Tradit West Med, 2019, 39(11): 1286-1295. DOI: 10.7661/j.cjim.20190916.314.

KETELUT-CARNEIRO N, FITZGERALD K A. Inflammasomes[J]. Curr Biol, 2020, 30(12): R689-R694. DOI: 10.1016/j.cub.2020.04.065.

INZAUGARAT M E, JOHNSON C D, HOLTMANN T M, et al . NLR family pyrin domain-containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice[J ] . Hepatology, 2019, 69(2): 845-859. DOI: 10.1002/hep.30252.

WREE A, MCGEOUGH M D, INZAUGARAT M E, et al . NLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice[J ] . Hepatology, 2018, 67(2): 736-749. DOI: 10.1002/hep.29523.

陆伦根, 尤红, 谢渭芬, 等. 肝纤维化诊断及治疗共识(2019年)[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.

LU L G, YOU H, XIE W F, et al . Consensus on the diagnosis and therapy of hepatic fibrosis[J ] . J Pract Hepatol, 2019, 22(6): 793-803.

国家药典委员会. 中华人民共和国药典(2010年版一部)[S]. 中国医药科技出版社, 2010: 163-164.

National Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China (2010 Volume 1)[S]. China Medical Science and Technology Press, 2010: 163-164.

冯杰鑫, 吴雄, 陈建辉, 等. 柴胡皂苷D通过下调JAK2/STAT3通路抑制乳腺癌细胞的增殖并促进其凋亡[J]. 第三军医大学学报, 2021, 43(9): 852-857. DOI: 10.16016/j.1000-5404.202010217.

FENG J X, WU X, CHEN J H, et al . Saikosaponin D inhibits proliferation and promotes apoptosis in breast cancer cells through down-regulating JAK2/STAT3 pathway[J ] . J Third Mil Med Univ, 2021, 43(9): 852-857. DOI: 10.16016/j.1000-5404.202010217.

JIANG J S, MENG Y F, HU S F, et al . Saikosaponin D: a potential therapeutic drug for osteoarthritis[J ] . J Tissue Eng Regen Med, 2020, 14(8): 1175-1184. DOI: 10.1002/term.3090.

阮君, 肖铁刚, 王兵. 柴胡皂苷D对非酒精性脂肪性肝炎大鼠糖脂代谢紊乱的影响[J]. 中西医结合肝病杂志, 2019, 29(5): 399-401.

RUAN J, XIAO T G, WANG B. Effects of Saikosaponin-D on glucose and lipid metabolism disorder in rats with non-alcoholic steatohepatitis[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29(5): 399-401.

王祎, 庞旭, 张保财, 等. 柴胡皂苷d对肝星状细胞的作用分析[J]. 北京化工大学学报(自然科学版), 2020, 47(5): 76-82. DOI: 10.13543/j.bhxbzr.2020.05.010.

WANG Y, PANG X, ZHANG B C, et al . Effects of sa ikosaponin D on hepatic stellate cells[J ] . J Beijing Univ Chem Technol Nat Sci Ed, 2020, 47(5): 76-82. DOI: 10.13543/j.bhxbzr.2020.05.010.

SHI Y, HUANG H H, CHEN C Y, et al . Reparative and toxicity-reducing effects of liposome-encapsulated saikosaponin in mice with liver fibrosis[J ] . Biosci Rep, 2020, 40(8): BSR20201219. DOI: 10.1042/BSR20201219.

张艳, 都广礼, 陈德兴, 等. 猪血清致大鼠免疫性肝纤维化的动态观察[J]. 中国中西医结合消化杂志, 2007, 15(2): 74-77. DOI: 10.3969/j.issn.1671-038X.2007.02.002.

ZHANG Y, DU G L, CHEN D X, et al . Dynamic observation of immune liver fibrosis in rats induced by porcine serum[J ] . Chin J Integr Tradit West Med Dig, 2007, 15(2): 74-77. DOI: 10.3969/j.issn.1671-038X.2007.02.002.

王宪东, 石安华, 陈文玲. 肝纤维化大鼠模型的研究进展[J]. 世界最新医学信息文摘, 2016, 16(94): 39-30. DOI: 10.3969/j.issn.1671-3141.2016.94.028.

WANG X D, SHI A H, CHEN W L. Progress on rat model of hepatic fibrosis[J]. World Latest Med, 2016, 16(94): 39-30. DOI: 10.3969/j.issn.1671-3141.2016.94.028.

李尧, 徐晓欧. 自身免疫性肝病的发病机制及诊疗进展[J]. 医学综述, 2021, 27(9): 1707-1711.

LI Y, XU X O. Pathogenesis and diagnosis and treatment of autoimmune liver diseases[J]. Med Recapitul, 2021, 27(9): 1707-1711.

赵琼, 刘恒军. 柴胡皂苷D对克雷伯杆菌肺炎大鼠肺组织损伤和纤维化及免疫功能的调节作用[J]. 沈阳药科大学学报, 2019, 36(9): 823-829. DOI: 10.14066/j.cnki.cn21-1349/r.2019.09.010.

ZHAO Q, LIU H J. The regulating effect of saikosaponin D on lung tissue injury, fibrosis and immune function in Klebsiella pneumoniae rats[J]. J Shenyang Pharm Univ, 2019, 36(9): 823-829. DOI: 10.14066/j.cnki.cn21-1349/r.2019.09.010.

李敏, 高凯, 王华林, 等. 柴胡皂苷d-黄芩苷配伍对CCl 4 诱导大鼠HSC的TLR4-NF-κB通路作用研究[J ] . 陕西中医, 2018, 39(1): 3-5.

LI M, GAO K, WANG H L, et al . Inhibitory effects of Saikosaponin D-Baicalin on activation of rat HSC induced by CCl 4 [J ] . Shaanxi J Tradit Chin Med, 2018, 39(1): 3-5..

郝健亨, 陈浩, 高艳, 等. 柴胡皂苷d对自身免疫性肝炎小鼠差异表达基因CTLA-4、IL-10和IL-17的影响[J]. 上海交通大学学报(医学版), 2020, 40(3): 303-309.

HAO J H, CHEN H, GAO Y, et al . Effects of saikosaponin D on differentially expressed genes CTLA-4, IL-10 and IL-17 in mice with autoimmune hepatitis[J ] . J Shanghai Jiao tong Univ Med Sci, 2020, 40(3): 303-309.

林柳兵, 阙任烨, 李毅平, 等. 柴胡皂苷d对急性肝损伤小鼠高迁移率族蛋白B1表达的影响[J]. 时珍国医国药, 2019, 30(3): 527-531. DOI: 10.3969/j.issn.1008-0805.2019.03.005.

LIN L B, QUE R Y, LI Y P, et al . Effect of Saikosaponin D on the expression of high mobility group box 1 in mice with acute liver injury[J ] . Lishizhen Med Materia Medica Res, 2019, 30(3): 527-531. DOI: 10.3969/j.issn.1008-0805.2019.03.005.

PLACE D E, KANNEGANTI T D. Recent advances in inflammasome biology[J]. Curr Opin Immunol, 2018, 50: 32-38. DOI: 10.1016/j.coi.2017.10.011.

王丹姝, 燕柳艳, 孙姝婵, 等. 葛根素通过TLR4/Myd88/NF-κB抑制NLRP3炎症小体抗大鼠心肌缺血再灌注损伤[J]. 药学学报, 2021, 56(5): 1343-1351. DOI: 10.16438/j.0513-4870.2021-0124.

WANG D S, YAN L Y, SUN S C, et al . Puerarin protects against myocardial ischemia/reperfusion injury by suppressing NLRP3 inflammasome activation via TLR4/Myd88/NF-κB pathway in rats[J ] . Acta Pharm Sin, 2021, 56(5): 1343-1351. DOI: 10.16438/j.0513-4870.2021-0124.

FISCHER F A, CHEN K W, BEZBRADICA J S. Posttranslational and therapeutic control of gasdermin-mediated pyroptosis and inflammation[J]. Front Immunol, 2021, 12: 661162. DOI: 10.3389/fimmu.2021.661162.

张娜, 晏旎, 周蒙恩, 等. 柴胡皂苷d对氧化应激诱导的人肝星状细胞活化后ROS形成及NLRP3炎性小体表达的影响[J]. 时珍国医国药, 2020, 31(4): 805-809. DOI: 10.3969/j.issn.1008-0805.2020.04.010.

ZHANG N, YAN N, ZHOU M E, et al . Effects of Saikosaponin D on ROS formation and NLRP3 inflammasome expression after oxidative stress-induced activation of human hepatic stellate cells[J ] . Lishizhen Med Materia Medica Res, 2020, 31(4): 805-809. DOI: 10.3969/j.issn.1008-0805.2020.04.010.

张娜, 李勇. 柴胡皂苷d对人肝细胞损伤的保护作用研究及抗肝纤维化机制探讨[J]. 中华中医药学刊, 2021, 39(12): 21-27, 275. DOI: 10.13193/j.issn.1673-7717.2021.12.005.

ZHANG N, LI Y. Study on protective effect of bupleurin D on human hepatocyte injury and mechanism of anti-liver fibrosis[J]. Chin Arch Tradit Chin Med, 2021, 39(12): 21-27, 275. DOI: 10.13193/j.issn.1673-7717.2021.12.005.

LIN L B, QUE R Y, SHEN Y T, et al . Saikosaponin-D alleviates carbon-tetrachloride induced acute hepatocellular injury by inhibiting oxidative stress and NLRP3 inflammasome activation in the HL-7702 cell line[J ] . Mol Med Rep, 2018, 17(6): 7939-7946. DOI: 10.3892/mmr.2018.8849.

CHEN Y R, QUE R Y, LIN L B, et al . Inhibition of oxidative stress and NLRP3 inflammasome by Saikosaponin-d alleviates acute liver injury in carbon tetrachloride-induced hepatitis in mice[J ] . Int J Immunopathol Pharmacol, 2020, 34: 2058738420950593. DOI: 10.1177/2058738420950593.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

高尿酸通过TLR4/NF-κB信号通路诱导肾小管上皮细胞上皮-间充质转化的作用研究

丁酸钠通过TLR4/NF-κB信号通路调控脂多糖诱导的BV2小胶质细胞表型极化

柴胡皂苷D通过下调JAK2/STAT3通路抑制乳腺癌细胞的增殖并促进其凋亡

NLRP3炎症小体激活在太赫兹暴露所致小鼠皮肤炎症中的作用

扶正化瘀胶囊联合替诺福韦治疗乙肝肝纤维化的疗效观察